Peptimmune
Cambridge
About Peptimmune
Peptimmune is a privately held clinical stage biotechnology company focused on utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders. The company is developing second generation therapeutics that are expected to result in safer and more effective products for obesity, multiple sclerosis, rheumatoid arthritis and pemphigus vulgaris.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $92.9M
- Funding stage: Late Stage Venture
- Last round: Series D (Jul 2008)
- Website: peptimmune.com
- Phone: 16172527977
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/peptimmune-756542 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.